License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2021

Summary of Revenues by Collaboration and by Category of Revenue

The following table summarizes details of revenues for the three and nine months ended September 30, 2021 and 2020 by collaboration and by category of revenue:

			Three Months Ended September 30,				Nine Months Ended September 30,
Revenues recognized:	Over time	Point in time	2021		2020		2021		2020
Gilead license to zimberelimab		*	$	-	$	55,096	$	-	$	55,096
Gilead access rights related to the Company's research and development pipeline	*			7,711		7,684		23,133		7,684
Taiho collaboration agreement	*			1,750		1,750		5,250		5,250
Total revenues			$	9,461	$	64,530	$	28,383	$	68,030

Summary of Revenue Recognized as a Result of Changes in Deferred Revenue

The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
Revenue recognized in the period from:	2021		2020		2021		2020
Amounts included in deferred revenue at the beginning of the period	$	9,461	$	1,750	$	28,383	$	5,250
Performance obligations satisfied in previous period		-		-		-		-

Gilead and Taiho

Summary of Revenues

The following table summarizes the revenues for the three and nine months ended September 30, 2021 and 2020 received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
License revenue	$	-	$	55,096	$	-	$	55,096
Collaboration revenue		9,461		9,434		28,383		12,934
Total revenues	$	9,461	$	64,530	$	28,383	$	68,030